Literature DB >> 9619785

Influence of indocyanine green on plasma disappearance and biliary excretion of a synthetic thrombin inhibitor of the 3-amidinophenyl-alanine piperazide-type in rats.

J Hauptmann1, J Stürzebecher.   

Abstract

PURPOSE: The pharmacokinetics of a number of synthetic peptidomimetic thrombin inhibitors is determined by extensive hepatic elimination. The objective was to further characterize the disposition in vivo of Pefa 1023, a novel 3-amidinophenylalanine piperazide-type thrombin inhibitor, by influencing the hepatic handling with indocyanine green (ICG), which is actively taken up by the liver.
METHODS: Pefa 1023 was administered intravenously to bile duct-cannulated rats, either alone or in combination with ICG. The concentrations of Pefa 1023 in blood plasma and bile were measured by a bioassay (thrombin clotting time), concentrations of indocyanine green were measured spectrophotometrically.
RESULTS: ICG (10 mg/kg i.v. 15 min prior to or simultaneously with Pefa 1023) markedly influenced the plasma level and biliary excretion rate of the thrombin inhibitor Pefa 1023 given in a dose of 1 mg/kg i.v. The plasma level was more than twice that of the control, the maximum biliary excretion rate about one third and the fraction of dose excreted in bile about two thirds.
CONCLUSIONS: The anionic dye ICG is able to interfere with the hepatic handling of a cationic, amidinophenylalanine piperazide-type thrombin inhibitor with the consequence of reduced hepatic clearance leading to higher plasma levels and lower biliary excretion of the latter.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619785     DOI: 10.1023/a:1011927204847

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants.

Authors:  J Hauptmann; F Markwardt
Journal:  Semin Thromb Hemost       Date:  1992       Impact factor: 4.180

2.  In vitro and in vivo comparison of arginine- and benzamidine-derived highly potent synthetic thrombin inhibitors.

Authors:  J Hauptmann; B Kaiser
Journal:  Pharmazie       Date:  1991-01       Impact factor: 1.267

Review 3.  Molecular properties of hepatic uptake systems for bile acids and organic anions.

Authors:  B Hagenbuch
Journal:  J Membr Biol       Date:  1997-11-01       Impact factor: 1.843

4.  An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.

Authors:  H Bounameaux; H Ehringer; J Hulting; H Rasche; H J Rapold; M Zultak
Journal:  Thromb Haemost       Date:  1997-09       Impact factor: 5.249

5.  Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.

Authors:  J Stürzebecher; D Prasa; J Hauptmann; H Vieweg; P Wikström
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

6.  Hepatic extraction of nonmetabolizable xenobiotics in rats.

Authors:  T Iga; C D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  1979-12       Impact factor: 4.030

Review 7.  Transport of organic anions in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport.

Authors:  E Petzinger
Journal:  Rev Physiol Biochem Pharmacol       Date:  1994       Impact factor: 5.545

8.  First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems.

Authors:  U Eckhardt; W Stüber; G Dickneite; M Reers; E Petzinger
Journal:  Biochem Pharmacol       Date:  1996-07-12       Impact factor: 5.858

Review 9.  Challenges in the development of orally bioavailable thrombin active site inhibitors.

Authors:  S D Kimball
Journal:  Blood Coagul Fibrinolysis       Date:  1995-09       Impact factor: 1.276

10.  [Animal experiments on the pharmacokinetics of N alpha-tosyl-(3-amidinophenyl)alanine piperidide (TAPAP), a new thrombin inhibitor].

Authors:  J Hauptmann; F Markwardt; M Richter
Journal:  Pharmazie       Date:  1982-06       Impact factor: 1.267

View more
  2 in total

1.  Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats.

Authors:  Yuji Mano; Takashi Usui; Hidetaka Kamimura
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

2.  Transport of peptidomimetic thrombin inhibitors with a 3-amidino-phenylalanine structure: permeability and efflux mechanism in monolayers of a human intestinal cell line (Caco-2).

Authors:  W Kamm; J Hauptmann; I Behrens; J Stürzebecher; F Dullweber; H Gohlke; M Stubbs; G Klebe; T Kissel
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.